archive-com.com » COM » H » HBMPARTNERS.COM

Total: 38

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • HBM Partners AG - HBM Healthcare Investments
    devices and diagnostics industries in Europe and US Two IPOs and eight trade sales from the portfolio so far have enabled HBM BioCapital I to return over 100 of the invested capital HBM BioCapital II HBM BioCapital II LP a private equity limited partnership with a capital of USD 120 million was launched in 2012 as follow on fund to HBM BioCapital I HBM BioCapital II invests in mainly European and also US private healthcare companies with a focus on growth companies Investments range between USD EUR 5 million to USD EUR 12 million So far the fund has invested in 4 companies HBM BioCapital II was supported with capital from the European Investment Fund www eif org Back Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund is A rated by Citywire for its

    Original URL path: http://www.hbmpartners.com/en/investment-products/hbm-overview-private-equity-investment-funds.php (2016-04-25)
    Open archived version from archive


  • HBM Partners AG - Press Releases
    Including Full Exercise of Underwriters Option to Purchase Additional Shares 793 KB 18 2 2014 PTC Joint program in spinal muscular atrophy enters first stage of clinical development 14 KB 22 1 2014 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2014/news-2014.php?pageIdc47bbb3f=2 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2011/news.php?pageIdc47bbb3f=2 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    19 04 2010 Lux Biosciences Luveniq receives FDA priority review 24 KB 30 03 2010 Lux Biosciences Luveniq receives FDA priority review 22 KB 30 03 2010 Anthera Pharmaceuticals completes Initial Public Offering 16 KB 04 03 2010 Abbott and Enanta announce advancement of Hepatitis C collaboration 27 KB 02 03 2010 Lux Biosciences files for Luveniq approval in US and Europe for noninfectious Uveitis 67 KB 04 02 2010 Kolltan Pharmaceuticals closes 10 million series B related financing 51 KB 20 01 2010 Asthmatx pivotal trial manuscript for Bronchial Thermoplasty published in the American Journal of Respiratory and Critical Care Medicine 67 KB 12 01 2010 GSK exercises option to progress development of ChemoCentryx s Traficet EN for the treatment of inflammatory bowel diseases 44 KB 11 01 2010 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2010/news.php?pageIdc47bbb3f=2 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    05 2009 mtm laboratories and MetaSystems agree on partnership to develop Automated CINtec Cytology Imaging System 39 KB 26 05 2009 Brahms for the first time a new Biomarker test enables detection of Alzheimer s dementia in blood 22 KB 15 05 2009 Diagnostics company BRAHMS presents positive results for 2008 19 KB 13 05 2009 Merck KGaA global partner of Newron initiates second phase III trial of safinamide in advanced Parkinson s disease 27 KB 07 05 2009 Anthera s varespladib meets primary endpoint in phase 2 FRANCIS trial for the treatment of acute coronary syndrome 40 KB 06 05 2009 Ophthotech s positive results for their Novel Therapy for Wet AMD 105 KB 04 05 2009 Lux reports first oral drug for uveitis which reduces both inflammation and recurrence rate in potientially blinding eye disease 85 KB 04 05 2009 Mpex s new CBO Mark Wiggins joins from Biogen Idec 19 KB 20 04 2009 Lux Biosciences reports positive results from LUMINATE Phase 3 program of LX211 LUVENIQ in Uveitis 95 KB 26 03 2009 ESBATech ESBA105 demonstrates efficacy in the back of the eye to inhabit neovascularization 47 KB 24 03 2009 Anthera s IMPACTS trial demonstrates favorable interim results in preventing sickle cell complication 18 KB 24 03 2009 Nereus Pharmaceuticals initiates randomized phase 2 clinical trial in non small cell lung cancer 15 KB 23 03 2009 MiCardia announces worlds first dynamic heart valve repair on a beating heart 253 KB 17 02 2009 Newron announces improved motor function in phase III Parkinson s trial of Safinamade 125 KB 03 02 2009 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2009/news.php?pageIdd8eea300=2 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    FDA clearance to market automated procalcitonin PCT test 25 KB 07 04 2008 ESBATech s antibody fragments demonstrate penetration into the eye with topical delivery via eye drops 220 KB 25 02 2008 Surface Logix reports phase 2A on SLX 4090 23 KB 29 01 2008 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2008/news.php?pageIdc47bbb3f=2 (2016-04-25)
    Open archived version from archive



  •